Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist.

[1]  N. Irwin,et al.  Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists , 2022, Diabetes, obesity & metabolism.

[2]  R. DiMarchi,et al.  Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice , 2022, Molecular metabolism.

[3]  Minrong Ai,et al.  GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior , 2022, Diabetes.

[4]  Zeyun Li,et al.  A GLP‐1/glucagon (GCG)/CCK2 receptors tri‐agonist provides new therapy for obesity and diabetes , 2022, British journal of pharmacology.

[5]  Xi Sun,et al.  Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis , 2021, Acta pharmaceutica Sinica. B.

[6]  M. Tschöp,et al.  Anti-obesity drug discovery: advances and challenges , 2021, Nature reviews. Drug discovery.

[7]  J. Hecksher-Sørensen,et al.  Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries , 2021, Molecular metabolism.

[8]  T. Borner,et al.  The Role of GIP in the Regulation of GLP-1 Satiety and Nausea , 2021, Diabetes.

[9]  C. Roth,et al.  Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis , 2021, Journal of medicinal chemistry.

[10]  B. Wulff,et al.  The design of a GLP-1/PYY dual acting agonist. , 2021, Angewandte Chemie.

[11]  Weizhong Tang,et al.  Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. , 2020, European journal of medicinal chemistry.

[12]  Wen Jiang,et al.  Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes. , 2020, Journal of medicinal chemistry.

[13]  A. Courcoulas,et al.  Benefits and Risks of Bariatric Surgery in Adults: A Review. , 2020, JAMA.

[14]  Matthew S. Tremblay,et al.  Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity. , 2020, Journal of medicinal chemistry.

[15]  Tao Ma,et al.  A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice. , 2020, European journal of medicinal chemistry.

[16]  M. Larsen,et al.  Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. , 2020, Nature metabolism.

[17]  P. Schultz,et al.  New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice. , 2020, Bioconjugate chemistry.

[18]  Søren L Pedersen,et al.  Half-Life Extending Modifications of Peptide YY3-36 Direct Receptor-Mediated Internalization. , 2019, Molecular pharmaceutics.

[19]  J. Holst,et al.  Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study , 2019, Diabetes Care.

[20]  L. B. Knudsen,et al.  The Discovery and Development of Liraglutide and Semaglutide , 2019, Front. Endocrinol..

[21]  M. Erion,et al.  A Long-Acting PYY3-36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates. , 2019, Cell metabolism.

[22]  B. Wulff,et al.  Design of Y2 Receptor Selective and Proteolytically Stable PYY3-36 Analogues. , 2018, Journal of medicinal chemistry.

[23]  M. Tschöp,et al.  Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases , 2018, Nature Reviews Endocrinology.

[24]  C. Roth,et al.  Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors , 2018, Scientific Reports.

[25]  C. Beglinger,et al.  Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial , 2018, JAMA.

[26]  Jing Han,et al.  Xenopus GLP‐1‐inspired discovery of novel GLP‐1 receptor agonists as long‐acting hypoglycemic and insulinotropic agents with significant therapeutic potential , 2017, Biochemical pharmacology.

[27]  Wen-long Huang,et al.  A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects. , 2017, European journal of medicinal chemistry.

[28]  T. S. Kobilka,et al.  Cryo-EM structure of the activated GLP-1 receptor in complex with G protein , 2017, Nature.

[29]  A. Evers,et al.  Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. , 2017, Journal of medicinal chemistry.

[30]  J. Holst,et al.  The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers , 2017, The Journal of clinical endocrinology and metabolism.

[31]  Deepak L. Bhatt,et al.  Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5‐Year Outcomes , 2017, The New England journal of medicine.

[32]  J. Meiler,et al.  Unwinding of the C-Terminal Residues of Neuropeptide Y is critical for Y₂ Receptor Binding and Activation. , 2015, Angewandte Chemie.

[33]  N. Irwin,et al.  A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat–Fed Mice , 2015, Diabetes.

[34]  R. Seeley,et al.  A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents , 2014, Nature Medicine.

[35]  J. Holst,et al.  Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass , 2014, Diabetes.

[36]  A. Miras,et al.  Mechanisms underlying weight loss after bariatric surgery , 2013, Nature Reviews Gastroenterology &Hepatology.

[37]  M. Yeh,et al.  Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. , 2013, Journal of hepatology.

[38]  J. Jelsing,et al.  The novel GLP‐1‐gastrin dual agonist, ZP3022, increases β‐cell mass and prevents diabetes in db/db mice , 2013, Diabetes, obesity & metabolism.

[39]  S. Bloom,et al.  Translational studies on PYY as a novel target in obesity. , 2011, Current opinion in pharmacology.

[40]  P. Pfluger,et al.  A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. , 2011, ACS chemical biology.

[41]  K. Wynne,et al.  PYY3–36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans , 2010, Diabetes.

[42]  P. Bonaventure,et al.  In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor , 2010, Psychopharmacology.